Catheter Ablation of Longstanding Persistent Atrial Fibrillation
NCT ID: NCT02929836
Last Updated: 2016-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
450 participants
INTERVENTIONAL
2016-05-31
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Value of Linear Ablation Without Pulmonary Vein Isolation in Persistent Atrial Fibrillation
NCT05468528
CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation
NCT05454111
Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation
NCT04497376
Left Atrial Appendage Closure in Combination With Catheter Ablation
NCT03788941
Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation
NCT02093949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PVI+LA linear ablation +CFAE ablation
The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
PVI
PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
LA linear ablation
LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
CFAE ablation
Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
CARTO
3 dimensional mapping system
PVI+linear ablation +CFAE ablation
The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
PVI
PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
LA linear ablation
LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
CFAE ablation
Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
linear ablation
Right atrial CTI ablation was performed during SR.
CARTO
3 dimensional mapping system
PVI+CFAE ablation
The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
PVI
PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
CFAE ablation
Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
CARTO
3 dimensional mapping system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PVI
PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
LA linear ablation
LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
CFAE ablation
Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
linear ablation
Right atrial CTI ablation was performed during SR.
CARTO
3 dimensional mapping system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Exhibited refractoriness to at least one antiarrhythmic drug
* Left atrial diameter \<=60mm
Exclusion Criteria
* Having significant valvular disease and/or prosthetic heart valve(s)
* With myocardial infarction or stroke within 6 months of screening
* With Significant congenital heart disease;ejection fraction was \<40% measured by echocardiography
* Allergic to contrast media
* Contraindication to warfarin or heparin
* Severe pulmonary disease e.g. restrictive pulmonary disease
* Chronic obstructive disease (COPD)
* Left atrial (LA) thrombus measured by pre-procedure transesophageal echocardiography
* Having any contraindication to right or left sided heart catheterization
* Poor general health
* Life expectancy less than 6 months
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Chest Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
wang yuanlong
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xu Mr Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Shanghai Chest Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai chest hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSL-20161002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.